AZ-WORLD-VIEW
17.3.2022 15:46:04 CET | Business Wire | Press release
World View , an expert in stratospheric exploration on a mission to help spaceflight participants rediscover Earth, today announces the debut of its spaceflight capsule prototype. The announcement marks another exciting milestone for the company, following recent news of its entry into the space tourism sector and appointment of President of Tourism and Exploration, Dale Hipsh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005669/en/
Spaceflight participants eagerly awaiting the launch of commercial flights beginning in 2024 are provided a first-look at the distinctive World View experience, from onboard amenities and design touches to the superior hospitality and life-changing perspectives enjoyed throughout the journey.
“Unveiling our space capsule prototype is a pivotal moment for the company as we continue to prepare for our first launch from the Grand Canyon in just two short years,” said Ryan Hartman, President and Chief Executive Officer of World View. “We are thrilled to partner with leaders in aerospace design and engineering to bring our vision to life and ensure spaceflight participants enjoy a truly transformative experience.”
The exterior of the World View space capsule is shaped like a faceted hexagon with softened edges and a pearlescent white finish, which offers thermal management properties but also enhances the geometric detailing and curves. It boasts large elliptical windows that measure approximately 6.5 feet wide x 4.5 feet high, framing impressive views of the Earth’s curvature and its natural wonders. When seats are in a reclined position, the sky window on top of the capsule provides passengers an exciting line of sight to the balloon lifting them as well as constellations upon reaching float altitude. The central ceiling pelmet also includes a mood wash light that changes in accordance with the stage in flight to provide optimal viewing out of the capsule’s windows.
The capsule is climate-controlled and pressurized with an entire interior designed to maximize space, allowing spaceflight participants to move freely and comfortably about the capsule. The color palette, materials and finishes create an environment of calm, with clean lines, soft tones and clever concealment of functional elements–such as lavatory and galley entrances–so the focus remains on the stunning vistas and sights outside. Aligned with World View’s commitment to sustainability, great care is being taken to ensure materials are sourced from sustainable vendors whenever possible and options for re-use or recycling are being thoroughly explored.
Luxurious, ergonomic seating for eight passengers is configured in pairs, with an additional pair designated for crew members. Amenities including a cocktail table, graphical user interface (GUI) screen (providing educational materials and engaging activities), central console, personal storage and beverage holder, are at spaceflight participants’ fingertips to ensure that no moment of the journey is missed. Each capsule is outfitted with an onboard telescope to maximize viewing throughout the journey. Spaceflight participants will also enjoy gourmet custom dining options and top-shelf libations throughout their flight and each capsule will be equipped with streaming and mobile communication capabilities to stay in touch with loved ones back on Earth.
Projected lift off is scheduled before dawn, providing participants a front row seat to the sunrise on most flights. Along the journey, passengers will take in the curvature of the Earth, thin blue line of the atmosphere, vast darkness of space and constellations. Without the typical turbulence found on an airplane flight, spaceflight participants will be able to stand and move about the craft shortly after launch. The onboard crew, including one pilot and one concierge, serve as both Earth and space guides, cross-trained in flight operations, hospitality and medical support.
World View’s space tourism program begins launching commercial flights in 2024 with voyages taking off from natural and man-made wonders such as the Grand Canyon and Great Barrier Reef. Flights will lift passengers in a zero-pressure stratospheric balloon and pressurized space capsule to 100,000 feet altitude, nearly 23 miles above Earth, for an unparalleled experience that will last six to eight hours. Participants will fully experience and immerse themselves in the beauty, fragility, history and importance of the areas surrounding each location and of the Earth itself.
Design elements and engineering considerations continue to be refined. Further information on World View available at worldview.space .
ABOUT WORLD VIEW
World View is the leading stratospheric exploration company on a mission to inspire the global community to rediscover Earth. Through both its legacy Stratollite imaging and newly launched space tourism and exploration businesses, World View is working to ensure its ultimate objective: honor the planet so that future generations will feel blessed to call it home. For more information, visit worldview.space .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005669/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom